Gregg H. Alton Sells 15000 Shares of Gilead Sciences, Inc. (GILD) Stock

Jeannie Matthews
January 14, 2018

The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. (NASDAQ:GILD) news were published by: Fool.com which released: "2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better" on January 12, 2018, also Seekingalpha.com with their article: "My Recession-Proof Strategy And Top Picks For 2018" published on January 10, 2018, Fool.com published: "Why 2017 Was a Year to Remember for Gilead Sciences, Inc." on January 05, 2018. It has underperformed by 16.70% the S&P500.

Conan Laughlin decreased its stake in Gilead Sciences Inc (GILD) by 50% based on its latest 2017Q3 regulatory filing with the SEC. Pekin Singer Strauss Asset Management bought 13,909 shares as the company's stock declined 8.05% while stock markets rallied. The institutional investor held 3,543 shares of the health care company at the end of 2017Q3, valued at $281,000, down from 18,590 at the end of the previous reported quarter.

Shares of Gilead Sciences (GILD) traded down $0.04 on Tuesday, reaching $79.02. The stock had a trading volume of 6,342,448 shares, compared to its average volume of 8,150,000.

BidaskClub cut shares of Gilead Sciences (NASDAQ:GILD) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning. It has underperformed by 38.50% the S&P500.

Orleans Capital Management Corp, which manages about $1.29 billion and $133.55 million US Long portfolio, decreased its stake in Entergy Corp (NYSE:ETR) by 4,063 shares to 6,889 shares, valued at $526,000 in 2017Q3, according to the filing.

Frustrations, tragedy mount for California mudslide town
But it's not known when many residents in Montecito can return, and widespread damage is likely to take months or longer to fix . And search-and-rescue workers found the 18th person killed in the disaster, an 87-year-old man discovered Friday in his home.

Microsoft (MSFT) Rating Reiterated by Wells Fargo & Co
The firm has a market capitalization of $679,500.00, a price-to-earnings ratio of 29.76, a P/E/G ratio of 2.06 and a beta of 0.99. The investment professionals in our partner's database now possess: 5.51 billion shares, down from 5.53 billion shares in 2017Q2.

Hess Corp (NYSE:HES) Stock Price While Sentiment Worsens
PPL Corporation (PPL ) in the last quarter reported its actual EPS of $0.56/share where the analyst estimated EPS was $0.53/share. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock.

Among 29 analysts covering AT&T Inc. Also, Director John W. Madigan sold 105,000 shares of the business's stock in a transaction on Friday, November 18th. The firm has "Market Perform" rating by Leerink Swann given on Thursday, October 19. The stock of AT&T Inc. On Thursday, October 5 the stock rating was maintained by Leerink Swann with "Market Perform". Deutsche Bank maintained Intercontinental Exchange, Inc. Robert W. Baird has "Neutral" rating and $235 target. The firm has "Buy" rating given on Friday, April 29 by UBS. (NYSE:ICE) earned "Buy" rating by Deutsche Bank on Thursday, August 6. The company was maintained on Friday, July 14 by Barclays Capital.

Agran Libbie increased its stake in shares of Gilead Sciences by 1.5% in the second quarter. Its up 0.10, from 0.93 in 2017Q2. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company's stock valued at $330,000 after buying an additional 32 shares during the period. Jennison Assoc Ltd holds 24,005 shares. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company's stock worth $33,445,000 after purchasing an additional 75,364 shares during the period. United Automobile Association, Texas-based fund reported 1.37 million shares. (NYSE:T). 59,389 were accumulated by Whalerock Point Prns Ltd Liability Corp. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company's stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. State Of Tennessee Treasury Department owns 984,609 shares. (NYSE:C). Appleton Ptnrs Ma owns 41,595 shares or 0.51% of their USA portfolio. North Star Invest reported 0.86% stake. (NASDAQ:GILD). Wealthtrust holds 0% of its portfolio in Gilead Sciences, Inc. Epoch Ptnrs Inc invested 1.28% in AT&T Inc. Following the completion of the sale, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. Fiduciary Tru stated it has 0.35% of its portfolio in Oracle Corporation (NYSE:ORCL). Winfield Assocs Incorporated has invested 0.01% in Oracle Corporation (NYSE:ORCL). (NYSE:T) for 550 shares.

Since August 1, 2017, it had 0 buys, and 11 sales for $41.13 million activity. Meyers James R sold 60,000 shares worth $4.99 million. Gilead Sciences Inc now has $103.22 billion valuation. (NASDAQ:GILD) for 3.65M shares. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. During the same quarter in the previous year, the business earned $2.75 earnings per share. analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year. The rating was initiated by Standpoint Research with "Buy" on Wednesday, February 3. 60,000 Gilead Sciences, Inc. Jefferies maintained the stock with "Buy" rating in Wednesday, October 5 report. First Heartland Consultants Inc. raised its holdings in Gilead Sciences by 0.4% in the 2nd quarter. The stock has "Buy" rating by Jefferies on Monday, June 12. Maxim Group upgraded the stock to "Buy" rating in Thursday, November 30 report. The firm's revenue was down 13.9% compared to the same quarter a year ago. Mizuho maintained the shares of GILD in report on Thursday, September 28 with "Buy" rating. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the company a "buy" rating in a research note on Wednesday, October 25th. The stock has "Outperform" rating by Oppenheimer on Thursday, February 11. As per Tuesday, March 15, the company rating was maintained by Jefferies. Gilead Sciences had a net margin of 44.43% and a return on equity of 97.51%.

Investors sentiment decreased to 1.12 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It improved, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts' consensus estimates of $2.13 by $0.14. The California-based Blume Cap Management Inc has invested 0.2% in Gilead Sciences, Inc. Cetera Advisor Netwr Ltd Liability Corp accumulated 35,813 shares. Hourglass Limited Com holds 3.71% or 213,964 shares. Baker Avenue Asset Management Lp reported 0.02% in Gilead Sciences, Inc. Scotia Inc, a Ontario - Canada-based fund reported 168,294 shares. (NASDAQ:GILD). Fagan Associate stated it has 1.38% in Gilead Sciences, Inc. (NASDAQ:GILD). First Western holds 1.73% in Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. Glenview Trust Co lifted its stake in shares of Gilead Sciences by 1.1% during the first quarter. Natl Mutual Insurance Federation Of Agricultural Cooperatives owns 0.04% invested in Gilead Sciences, Inc. (NYSE:C). Moreover, D L Carlson Investment Grp Inc Inc has 2.09% invested in Citigroup Inc. Yhb Advisors holds 0.41% or 28,010 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER